Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer

Brief summary public domain (ClinicalTrials.gov)

This phase II trial is studying how well RO4929097 (gamma-secretase/Notch signalling pathway inhibitor RO4929097) works in treating patients with previously treated metastatic pancreatic cancer. RO4929097 may stop the growth of tumor cells by blocking some enzymes needed for cell growth.

Detailed description public domain (ClinicalTrials.gov)

PRIMARY OBJECTIVES: I. To determine the 6-month survival of patients with previously treated metastatic pancreas cancer treated with gamma secretase RO4929097. II. To determine the adverse events of RO4929097 in this patient population. III. To correlate changes in tumor markers with RO4929097 exposure. SECONDARY OBJECTIVES: I. To evaluate the response rate and overall survival of this population treated with RO4929097. II. To correlate clinical outcome with tumor markers (including stem cell markers) obtained from pre- and post- treatment biopsies. (exploratory) III. To assess variants in genes involved in RO4929097 disposition and their relation to RO4929097 exposure. OUTLINE: This is a multicenter study. Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 orally (PO) once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients may undergo tumor biopsy at baseline and on days 16 or 17 of course one for biomarker and other correlative studies. Blood samples may also collected at baseline and periodically during study for pharmacokinetic and angiogenesis marker studies. After completion of study therapy, patients are followed up periodically for 2 years.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Survival Rate [6 months]. Number, participants. Treatment (RO4929097) (n=18): 5.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Survival [From registration to death due to any cause, assessed up to 2 years]. Median, months (95% Confidence Interval). Treatment (RO4929097) (n=18): 4.1 (2.7 to 5.8).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Time to Disease Progression [From registration to documentation of disease progression, assessed up to 2 years]. Median, months (95% Confidence Interval). Treatment (RO4929097) (n=18): 1.5 (1.3 to 1.6).